Jaen Juan C. Form 4 February 19, 2013

### FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**SECURITIES** 

Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

Check this box if no longer subject to Section 16. Form 4 or Form 5

Form 4 or
Form 5
obligations
may continue.

See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person 2

Jaen Juan C.

Symbol
ChemoCentryx, Inc. [CCXI]

(Last) (First) (Middle) 3. Date of Earliest Transaction

(Month/Day/Year) 02/15/2013

C/O CHEMOCENTRYX, INC., 850 MAUDE AVENUE

(Street) 4. If Amendment, Date Original Filed(Month/Day/Year)

2. Issuer Name and Ticker or Trading
5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

\_\_\_\_ Director \_\_\_\_ 10% Owner
\_X\_\_ Officer (give title \_\_\_\_ Other (specify below)

SVP, Drug Discovery & CSO

6. Individual or Joint/Group Filing(Check

**OMB APPROVAL** 

3235-0287

January 31,

2005

0.5

OMB

Number:

Expires:

response...

Estimated average

burden hours per

Applicable Line)

\_X\_ Form filed by One Reporting Person \_\_\_\_ Form filed by More than One Reporting

Person

#### MOUNTAIN VIEW, CA 94043

(City)	(State)	(Zip) Tab	le I - Non-	Derivativ	e Secu	rities Acqui	red, Disposed of,	or Beneficial	ly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactic Code (Instr. 8)	omr Dispo (Instr. 3,	esed of 4 and (A) or		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/15/2013		M	1,245	A	\$ 4.3	54,245	D	
Common Stock	02/15/2013		S <u>(1)</u>	1,245	D	\$ 11.7114 (2)	53,000	D	
Common Stock	02/15/2013		M	700	A	\$ 4.3	53,700	D	
Common Stock	02/15/2013		S	700	D	\$ 11.7771 (3)	53,000	D	

#### Edgar Filing: Jaen Juan C. - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number owf Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	\$ 4.3	02/15/2013		M	1,245	<u>(4)</u>	02/06/2017	Common Stock	1,245
Employee Stock Option (right to buy)	\$ 4.3	02/15/2013		M	700	<u>(4)</u>	02/06/2017	Common Stock	700

## **Reporting Owners**

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			

Jaen Juan C.

C/O CHEMOCENTRYX, INC.
850 MAUDE AVENUE
MOUNTAIN VIEW, CA 94043
SVP, Drug Discovery & CSO

### **Signatures**

/s/ Susan M. Kanaya, as Attorney-in-Fact 02/19/2013

\*\*Signature of Reporting Person Date

Reporting Owners 2

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
  - Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from \$11.65 to
- (2) \$11.80 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
  - Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from \$11.75 to
- (3) \$11.83 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
- (4) As of February 15, 2013 and prior to this transaction, the option fully vested.
- (5) Not applicable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.